The role of potassium in atherosclerosis.
Atherosclerosis
/ metabolism
Cell Proliferation
Endothelium, Vascular
/ physiopathology
Free Radicals
/ metabolism
Humans
KATP Channels
/ metabolism
Lipoproteins, LDL
/ metabolism
Membrane Potentials
Muscle, Smooth, Vascular
/ metabolism
Myocytes, Smooth Muscle
/ metabolism
Potassium
/ metabolism
Potassium Channels, Calcium-Activated
/ metabolism
Potassium Channels, Inwardly Rectifying
/ metabolism
Shaker Superfamily of Potassium Channels
/ metabolism
atherosclerosis
ion channel
potassium
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
01
09
2020
revised:
04
11
2020
accepted:
15
11
2020
pubmed:
21
11
2020
medline:
30
11
2021
entrez:
20
11
2020
Statut:
ppublish
Résumé
Atherosclerosis (AS) is a chronic progressive inflammatory condition with a leading prevalence worldwide. Endothelial dysfunction leads to low-density lipoprotein trafficking into subendothelial space and the subsequent form of oxidized LDL (ox-LDL) within intimal layer, perpetuating the vicious cycle of endothelial dysfunction. K+ exerts beneficial effects in vascular wall by reducing LDL oxidization, vascular smooth muscle cells (VSMCs) proliferation, and free radical generation. K+ also modulates vascular tone through a regulatory effect on cell membrane potential. The most relevant papers on the association between 'potassium channels' and 'atherosclerosis' were selected among those deposited on PubMed from 1990 to 2020. Here, we provide a short narrative review that elaborates on the role of K+ in atherosclerosis. This review also update the current knowledge about potential pharmacological agents targeting K+ channels with a special focus on pleiotropic activities of agents such as statins, sulfonylureas and dihydropyridines. In this review, the mechanism of different K+ channels on vascular endothelium will be summarized, mainly focusing on their pathophysiological role in atherosclerosis and potential therapeutic application.
Sections du résumé
BACKGROUND
BACKGROUND
Atherosclerosis (AS) is a chronic progressive inflammatory condition with a leading prevalence worldwide. Endothelial dysfunction leads to low-density lipoprotein trafficking into subendothelial space and the subsequent form of oxidized LDL (ox-LDL) within intimal layer, perpetuating the vicious cycle of endothelial dysfunction. K+ exerts beneficial effects in vascular wall by reducing LDL oxidization, vascular smooth muscle cells (VSMCs) proliferation, and free radical generation. K+ also modulates vascular tone through a regulatory effect on cell membrane potential.
MATERIALS AND METHODS
METHODS
The most relevant papers on the association between 'potassium channels' and 'atherosclerosis' were selected among those deposited on PubMed from 1990 to 2020.
RESULTS
RESULTS
Here, we provide a short narrative review that elaborates on the role of K+ in atherosclerosis. This review also update the current knowledge about potential pharmacological agents targeting K+ channels with a special focus on pleiotropic activities of agents such as statins, sulfonylureas and dihydropyridines.
CONCLUSION
CONCLUSIONS
In this review, the mechanism of different K+ channels on vascular endothelium will be summarized, mainly focusing on their pathophysiological role in atherosclerosis and potential therapeutic application.
Substances chimiques
Free Radicals
0
KATP Channels
0
Lipoproteins, LDL
0
Potassium Channels, Calcium-Activated
0
Potassium Channels, Inwardly Rectifying
0
Shaker Superfamily of Potassium Channels
0
oxidized low density lipoprotein
0
Potassium
RWP5GA015D
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13454Informations de copyright
© 2020 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.
Références
Li M, Qian M, Kyler K, Xu J. Endothelial-vascular smooth muscle cells interactions in atherosclerosis. Front Cardiovas Med. 2018;5:151.
Fhayli W, Boëté Q, Harki O, Briançon-Marjollet A, Jacob M-P, Faury G. Rise and fall of elastic fibers from development to aging. Consequences on arterial structure-function and therapeutical perspectives. Matrix Biol. 2019;84:41-56.
Zhang W, Lei XJ, Wang YF, Wang DQ, Yuan ZY. Role of Kir2. 1 in human monocyte-derived foam cell maturation. J Cell Mol Med. 2016;20(3):403-412.
Sun Y, Byon CH, Yang Y, et al. Dietary potassium regulates vascular calcification and arterial stiffness. JCI Insight. 2017;2(19).
Graham UM, McCance DR, Young IS, Mullan KR. A randomised controlled trial evaluating the effect of potassium supplementation on vascular function and the renin-angiotensin-aldosterone system. J Hum Hypertens. 2014;28(5):333-339.
Young DB, Lin H, McCabe RD. Potassium's cardiovascular protective mechanisms. Am J Physiol. 1995;268(4 Pt 2):R825-R837.
Dogan MF, Yildiz O, Arslan SO, Ulusoy KG. Potassium channels in vascular smooth muscle: a pathophysiological and pharmacological perspective. Fundam Clin Pharmacol. 2019;33(5):504-523.
Cheng J, Wen J, Wang N, Wang C, Xu Q, Yang Y. Ion channels and vascular diseases. Arterioscler Thromb Vasc Biol. 2019;39(5):e146-e156.
Bondarenko AI, Panasiuk O, Okhai I, Montecucco F, Brandt KJ, Mach F. Ca2+-dependent potassium channels and cannabinoid signaling in the endothelium of apolipoprotein E knockout mice before plaque formation. J Mol Cell Cardiol. 2018;115:54-63.
Yang L, Doshi D, Morrow J, Katchman A, Chen X, Marx SO. Protein kinase C isoforms differentially phosphorylate Cav1. 2 α1c. Biochemistry. 2009;48(28):6674-6683.
Climent B, Sánchez A, Moreno L, et al. Underlying mechanisms preserving coronary basal tone and NO-mediated relaxation in obesity: Involvement of β1 subunit-mediated upregulation of BKCa channels. Atherosclerosis. 2017;263:227-236.
Mathew John C, Khaddaj Mallat R, George G, Kim T, Mishra RC, Braun AP. Pharmacologic targeting of endothelial Ca2+-activated K+ channels: a strategy to improve cardiovascular function. Channels. 2018;12(1):126-136.
Bi D, Toyama K, Lemaître V, et al. The intermediate conductance calcium-activated potassium channel KCa3. 1 regulates vascular smooth muscle cell proliferation via controlling calcium-dependent signaling. J Biol Chem. 2013;288(22):15843-15853.
Zhu Y-R, Jiang X-X, Zhang D-M. Critical regulation of atherosclerosis by the KCa3. 1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis. J Mol Med. 2019;97(9):1219-1229.
Toyama K, Wulff H, Chandy KG, et al. The intermediate-conductance calcium-activated potassium channel KCa3. 1 contributes to atherogenesis in mice and humans. J Clin Investig. 2008;118(9):3025-3037.
Xu R, Li C, Wu Y, et al. Role of KCa3. 1 channels in macrophage polarization and its relevance in atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 2017;37(2):226-236.
Wang X-C, Sun W-T, Yu C-M, et al. ER stress mediates homocysteine-induced endothelial dysfunction: modulation of IKCa and SKCa channels. Atherosclerosis. 2015;242(1):191-198.
Clapp LH, Tinker A. Potassium channels in the vasculature. Curr Opin Nephrol Hypertens. 1998;7(1):91-98.
Pongs O. Molecular biology of voltage-dependent potassium channels. Physiol Rev. 1992;72(suppl_4):S69-S88.
Duprat F, Guillemare E, Romey G, et al. Susceptibility of cloned K+ channels to reactive oxygen species. Proc Natl Acad Sci. 1995;92(25):11796-11800.
Gutterman DD, Miura H, Liu Y. Redox modulation of vascular tone: focus of potassium channel mechanisms of dilation. Arterioscler Thromb Vasc Biol. 2005;25(4):671-678.
Li H, Chai Q, Gutterman DD, Liu Y. Elevated glucose impairs cAMP-mediated dilation by reducing Kv channel activity in rat small coronary smooth muscle cells. Am J Physiol Heart Circul Physiol. 2003;285(3):H1213-H1219.
Villalonga N, David M, Bielańska J, et al. Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1. 3 voltage-dependent potassium channels. Biochem Pharmacol. 2010;80(6):858-866.
Kazama I, Tamada T, Tachi M. Usefulness of targeting lymphocyte Kv1. 3-channels in the treatment of respiratory diseases. Inflamm Res. 2015;64(10):753-765.
Wu X, Xu R, Cao M, Ruan L, Wang X, Zhang C. Effect of the Kv1. 3 voltage-gated potassium channel blocker PAP-1 on the initiation and progress of atherosclerosis in a rat model. Heart Vessels. 2015;30(1):108-114.
Dumitriu IE, Baruah P, Finlayson CJ, et al. High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+ CD28null T cells in patients with acute coronary syndrome. Circ Res. 2012;110(6):857-869.
Dumitriu IE, Araguás ET, Baboonian C, Kaski JC. CD4+ CD28null T cells in coronary artery disease: when helpers become killers. Cardiovasc Res. 2009;81(1):11-19.
Kan X-H, Gao H-Q, Ma Z-Y, et al. 3 potassium channel mediates macrophage migration in atherosclerosis by regulating ERK activity. Arch Biochem Biophys. 2016;591:150-156.
Bähring R, Milligan CJ, Vardanyan V, et al. Coupling of voltage-dependent potassium channel inactivation and oxidoreductase active site of Kvβ subunits. J Biol Chem. 2001;276(25):22923-22929.
Bahorun T, Soobrattee M, Luximon-Ramma V, Aruoma O. Free radicals and antioxidants in cardiovascular health and disease. Int J Med Update. 2006;1(2):25-41.
Stowasser M. Potassium Channel Mutations and Human Disease: Focus on Adrenal Hypertension. Molecular, Genetic, and Nutritional Aspects of Major and Trace Minerals. Elsevier; 2017;503-516.
Lee SM, Nguyen D, Hu Z, Abbott GW. Kcne2 deletion promotes atherosclerosis and diet-dependent sudden death. J Mol Cell Cardiol. 2015;87:148-151.
Miura T, Miki T. GSK-3β, a therapeutic target for cardiomyocyte protection. Circ J. 2009;73(7):1184-1192.
Watcharasit P, Bijur GN, Song L, Zhu J, Chen X, Jope RS. Glycogen synthase kinase-3β (GSK3β) binds to and promotes the actions of p53. J Biol Chem. 2003;278(49):48872-48879.
Hu Z, Crump SM, Zhang P, Abbott GW. Kcne2 deletion attenuates acute post-ischaemia/reperfusion myocardial infarction. Cardiovasc Res. 2016;110(2):227-237.
Inoue I, Nagase H, Kishi K, Higuti T. ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature. 1991;352(6332):244-247.
Quesada I, Rovira JM, Martin F, Roche E, Nadal A, Soria B. Nuclear KATP channels trigger nuclear Ca2+ transients that modulate nuclear function. Proc Natl Acad Sci. 2002;99(14):9544-9549.
Drain P. ATP and sulfonylurea linkage in the KATP channel solves a diabetes puzzler. Diabetes. 2013;62(11):3666-3668.
Hund TJ, Mohler PJ. Differential roles for SUR subunits in KATP channel membrane targeting and regulation. Am J Physiol Heart Circ Physiol. 2011;300(1):H33-H35.
Aquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev Cardiovasc Ther. 2010;8(3):359-372.
Lee KY, Kim J-R, Choi HC. Gliclazide, a KATP channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKKβ-AMPK pathway. Vascul Pharmacol. 2018;102:21-28.
Lam D, Schlichter LC. Expression and contributions of the Kir2. 1 inward-rectifier K+ channel to proliferation, migration and chemotaxis of microglia in unstimulated and anti-inflammatory states. Front Cell Neurosci. 2015;9:185.
Zhang Y-Y, Li G, Che H, et al. Effects of BKCa and Kir2. 1 channels on cell cycling progression and migration in human cardiac c-kit+ progenitor cells. PLoS One. 2015;10(9):e0138581. https://doi.org/10.1371/journal.pone.0138581
Qiao Y, Tang C, Wang Q, et al. 1 regulates rat smooth muscle cell proliferation, migration, and post-injury carotid neointimal formation. Biochem Biophys Res Comm. 2016;477(4):774-780.
Sobey CG. Potassium channel function in vascular disease. Arterioscler Thromb Vasc Biol. 2001;21(1):28-38.
Wang L, Zheng J, Du Y, et al. Cartilage oligomeric matrix protein maintains the contractile phenotype of vascular smooth muscle cells by interacting with 7β1 integrin. Circ Res. 2010;106(3):514.
Wang Z, Wang D-Z, Hockemeyer D, McAnally J, Nordheim A, Olson EN. Myocardin and ternary complex factors compete for SRF to control smooth muscle gene expression. Nature. 2004;428(6979):185-189.
Bernheim L, Bader CR. Human myoblast differentiation: Ca2+ channels are activated by K+ channels. Physiology. 2002;17(1):22-26.
Konig S, Béguet A, Bader CR, Bernheim L. The calcineurin pathway links hyperpolarization (Kir2. 1)-induced Ca2+ signals to human myoblast differentiation and fusion. Development. 2006;133(16):3107-3114.
Cheng J, Wen J, Wang N, Wang C, Xu Q, Yang Y. Ion Channels and Vascular Diseases. Arterioscler Thromb Vasc Biol. 2019;39(5):e146-e156.
Nieves-Cintrón M, Flores-Tamez VA, Le T, Baudel MM, Navedo MF. Cellular and molecular effects of hyperglycemia on ion channels in vascular smooth muscle. Cellular and Molecular Life Sciences. 2020. https://doi.org/10.1007/s00018-020-03582-z
Rainbow RD, Hardy ME, Standen NB, Davies NW. Glucose reduces endothelin inhibition of voltage-gated potassium channels in rat arterial smooth muscle cells. J Physiol. 2006;575(Pt 3):833-844.
Iadecola C. The neurovascular unit coming of age: a journey through neurovascular coupling in health and disease. Neuron. 2017;96(1):17-42.
Lu T, He T, Katusic ZS, Lee HC. Molecular mechanisms mediating inhibition of human large conductance Ca2+-activated K+ channels by high glucose. Circ Res. 2006;99(6):607-616.
Kinoshita H, Matsuda N, Kaba H, et al. Roles of phosphatidylinositol 3-kinase-Akt and NADPH oxidase in adenosine 5'-triphosphate-sensitive K+ channel function impaired by high glucose in the human artery. Hypertension. 2008;52(3):507-513.
Levitan I, Fang Y, Rosenhouse-Dantsker A, Romanenko V. Cholesterol and ion channels. Sub Cell Biochem. 2010;51:509-549.
Purcell EK, Liu L, Thomas PV, Duncan RK. Cholesterol influences voltage-gated calcium channels and BK-type potassium channels in auditory hair cells. PLoS One. 2011;6(10):e26289.
Wang S, Ran Y, Chen X, Li C, Cheng S, Liu J. Pleiotropic effects of simvastatin on the regulation of potassium channels in monocytes. Front Pharmacol. 2020;11:101.
Chruściel P, Sahebkar A, Rembek-Wieliczko M, et al. Impact of statin therapy on plasma adiponectin concentrations: A systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194-208. https://doi.org/10.1016/j.atherosclerosis.2016.07.897
Gorabi AM, Kiaie N, Bianconi V, Jamialahmadi T, Al-Rasadi K, Johnston TP, Pirro M, Sahebkar A. Antiviral effects of statins. Progress in Lipid Research. 2020;79:101054. https://doi.org/10.1016/j.plipres.2020.101054
Parizadeh SMR, Azarpazhooh MR, Moohebati M, et al. Simvastatin Therapy Reduces Prooxidant-Antioxidant Balance: Results of a Placebo-Controlled Cross-Over Trial. Lipids. 2011;46(4):333-340. https://doi.org/10.1007/s11745-010-3517-x
Bagheri H, Ghasemi F, Barreto GE, et al. The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic review. BioFactors. 2020;46 (3):309-325. https://doi.org/10.1002/biof.1597
Sahebkar A, Serban C, Ursoniu S, et al. The impact of statin therapy on plasma levels of von Willebrand factor antigen. Thrombosis and Haemostasis. 2016;115(03):520-532. https://doi.org/10.1160/th15-08-0620
Serban C, Sahebkar A, Ursoniu S, et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Scientific Reports. 2015;5(1). https://doi.org/10.1038/srep09902
Lee KY, Kim JR, Choi HC. Gliclazide, a K(ATP) channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKKβ-AMPK pathway. Vascul Pharmacol. 2018;102:21-28.
Wu X, Xu R, Cao M, Ruan L, Wang X, Zhang C. Effect of the Kv1.3 voltage-gated potassium channel blocker PAP-1 on the initiation and progress of atherosclerosis in a rat model. Heart Vessels. 2015;30(1):108-114.
Christophersen P, Wulff H. Pharmacological gating modulation of small- and intermediate-conductance Ca(2+)-activated K(+) channels (KCa2.x and KCa3.1). Channels. 2015;9(6):336-343.
Jørgensen S, Dyhring T, Brown DT, Strøbaek D, Christophersen P, Demnitz J. A high-throughput screening campaign for detection of ca(2+)-activated k(+) channel activators and inhibitors using a fluorometric imaging plate reader-based tl(+)-influx assay. Assay Drug Dev Technol. 2013;11(3):163-172.
Nguyen HM, Singh V, Pressly B, Jenkins DP, Wulff H, Yarov-Yarovoy V. Structural insights into the atomistic mechanisms of action of small molecule inhibitors targeting the KCa3.1 channel pore. Mol Pharmacol. 2017;91(4):392-402.
Du RH, Lu M, Wang C, Ding JH, Wu G, Hu G. The pore-forming subunit Kir6.1 of the K-ATP channel negatively regulates the NLRP3 inflammasome to control insulin resistance by interacting with NLRP3. Exp Mol Med. 2019;51(8):1-13.
Mei Y, Fang C, Ding S, et al. PAP-1 ameliorates DSS-induced colitis with involvement of NLRP3 inflammasome pathway. Int Immunopharmacol. 2019;75:105776.